Drug Trial Radar · NCT05421663
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
166
Actual
Start
Aug 12, 2022
Primary completion
Jul 30, 2041
Study completion Jul 30, 2041
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).
Conditions
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
Interventions
JNJ-90014496Biological
JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)20 and CD19.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Occurrence of Adverse Events (AEs) [Safety and Tolerability]Time frame: Up to 15 Years post JNJ-90014496 infusion
- Phase 2: Overall Response (OR) As Assessed by Independent Review Committee (IRC)Time frame: Up to 6 months post last participant's JNJ-90014496 infusion
Locations
32 sites in 8 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Colorado Blood Cancer Institute
Denver, Colorado
University of Iowa Hospital and Clinics
Iowa City, Iowa
University of Kentucky Medical Center
Lexington, Kentucky
Rutgers Cancer Institute of New Jersey
Piscataway, New Jersey
Levine Cancer Institute
Charlotte, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Greco Hainesworth Tennessee Oncology Centers for Research
Nashville, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee
St. David's South Austin Medical Center
Austin, Texas
MD Anderson Cancer Center
Houston, Texas
Texas Transplant Institute
San Antonio, Texas
Swedish Cancer Institute
Seattle, Washington
St Vincents Hospital Melbourne
Fitzroy, Australia
The Alfred Hospital
Melbourne, Australia
Fiona Stanley Hospital
Murdoch, Australia
Calvary Mater Newcastle Hospital
Waratah, Australia
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, Canada
Rigshospitalet
Copenhagen, Denmark
Odense University Hospital
Odense, Denmark
Erasmus MC
Rotterdam, Netherlands
UMC Utrecht
Utrecht, Netherlands
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hosp Univ Vall D Hebron
Barcelona, Spain
Hosp Clinic de Barcelona
Barcelona, Spain
ICO L'Hospitalet - Hospital Duran i Reynals
Barcelona, Spain
Hosp Univ Fund Jimenez Diaz
Madrid, Spain
University College London Hospitals
London, United Kingdom
The Christie NHS Foundation Trust Christie Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.